Trial Profile
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Midazolam (Primary)
- Indications Status epilepticus
- Focus Therapeutic Use
- Sponsors Shire; Takeda
- 10 Feb 2021 Status changed from recruiting to completed.
- 18 Feb 2020 Planned End Date changed from 27 Nov 2019 to 31 Dec 2020.
- 18 Feb 2020 Planned primary completion date changed from 27 Nov 2019 to 31 Dec 2020.